You have a leader in Precision Medicine
The Henry Ford Cancer Institute’s Precision Medicine program is the first and most comprehensive in Michigan to offer genomic testing and expertise of a molecular tumor board to all cancer patients.
Henry Ford Cancer Institute’s commitment to Precision Medicine was introduced in June 2016 as part of the White House’s Cancer Moonshot initiative. The HFCI Medical Director Steven Kalkanis, M.D., joined our Precision Medicine partner Syapse, at the Cancer Moonshot Summit in Washington, D.C., to announce a program to bring the most advanced cancer care to the Midwest. A huge step forward in cancer care, Precision Medicine provides advanced treatment options to patients where in many cases hope was not present.
Our visionary work with international glioblastoma and clinical trials experts led to another major step forward for precision medicine. We were first-in-the-world to enroll a patient in the GBM AGILE (Adaptive Global Innovative Learning Environment) Trial, aimed at identifying the most effective therapies for patients with the most aggressive form of brain cancer.
We reaffirmed our commitment to precision medicine and to paving a path for health systems to share data for cutting edge cancer treatment in September 2018 at the Biden Cancer Summit. Dr. Kalkanis was among a select group to take center stage for precision medicine at the national summit in Washington, D.C.
Henry Ford also is among a few select health systems in the country chosen to participate in All of Us, a National Institutes of Health Precision Medicine research program.